TOPnatalizumabnatalizumab-associatedRRMSrelapsing-remitting multiple sclerosisNCT00493298SPMS
…ontinued natalizumab after ≥1 year.Results As of November 2023, TOP enrolled 6319 patients. Median time on natalizumab was 4.13 yea…
1articles mentioning institutions
2institution mentions
1distinct institutions extracted
0%of mentions human-reviewed
Active filtersEntity: TOP ×
TOP
This institution is selected. Its supporting articles are shown below.